CommercialPrior AuthLow impact
[Georgia] Precertification list change notification
Anthem BCBS·GA · Hematology, Oncology, Pediatrics·Provider Bulletin
Effective date
Jan 1, 2027
We identified it
Jun 19, 2026
Summary
Anthem Blue Cross and Blue Shield Georgia is adding Gene Therapy for Wiskott-Aldrich Syndrome (MED.00161) to their precertification requirements effective January 1, 2027. This specialized gene therapy will require prior authorization before treatment to avoid reimbursement complications.
Action Required
Before January 1, 2027: Billing team must update prior authorization procedures to require precertification for Gene Therapy for Wiskott-Aldrich Syndrome (criteria MED.00161). Providers treating this rare condition should verify member eligibility through Availity Essentials at https://Availity.com or call the member ID card number. Failure to obtain precertification may result in reimbursement complications.